No results were found for your search. Please adjust your search term or broaden your search criteria.
Still can't find what you are looking for? We can prepare Custom Research for you.
Savaysa (edoxaban) is a hematological drug used to reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation. It is also used to treat deep vein thrombosis and pulmonary embolism. Savaysa is a direct factor Xa inhibitor, which works by blocking the action of factor Xa, a protein involved in the clotting process. This helps to reduce the risk of blood clots forming in the body.
Savaysa is marketed by Daiichi Sankyo, a Japanese pharmaceutical company. The drug was approved by the US Food and Drug Administration in 2015 and is now available in the US, Europe, and other countries.
The Savaysa market is highly competitive, with several other direct factor Xa inhibitors available, such as Eliquis (apixaban), Xarelto (rivaroxaban), and Pradaxa (dabigatran). These drugs are all used to reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation.
Companies in the Savaysa market include Daiichi Sankyo, Bristol-Myers Squibb, Pfizer, Bayer, and Boehringer Ingelheim. Show Less Read more
